| Cox regression | Competing risk regression | ||
---|---|---|---|---|
Crude HR | Adjusted HR | Crude sHR | Adjusted sHR | |
Opportunistic infections | ||||
 SLE | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
 PM/DM | 1.38 (1.26–1.51) | 1.18 (1.08–1.29) | 1.22 (1.11–1.34) | 1.17 (1.07–1.29) |
 SSc | 0.75 (0.67–0.85) | 0.58 (0.51–0.65) | 0.70 (0.62–0.78) | 0.67 (0.59–0.75) |
 RA | 0.61 (1.26–1.51) | 0.46 (0.44–0.48) | 0.62 (0.59–0.65) | 0.59 (0.57–0.62) |
 pSS | 0.57 (0.54–0.60) | 0.42 (0.39–0.44) | 0.58 (0.55–0.61) | 0.56 (0.53–0.59) |
Non-herpes zoster opportunistic infections | ||||
 SLE | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
 PM/DM | 1.63 (1.41–1.89) | 1.22 (1.05–1.42) | 1.44 (1.24–1.68) | 1.22 (1.05–1.43) |
 SSc | 0.83 (0.68–1.01) | 0.55 (0.45–0.67) | 0.77 (0.64–0.93) | 0.65 (0.54–0.79) |
 RA | 0.50 (0.47–0.54) | 0.33 (0.30–0.36) | 0.51 (0.47–0.55) | 0.45 (0.42–0.49) |
 pSS | 0.38 (0.34–0.42) | 0.25 (0.22–0.28) | 0.39 (0.34–0.43) | 0.35 (0.31–0.39) |